A Phase 2b, Dose-ranging Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults With Systemic Lupus Erythematosus

Trial Profile

A Phase 2b, Dose-ranging Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults With Systemic Lupus Erythematosus

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Jun 2017

At a glance

  • Drugs Sifalimumab (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Therapeutic Use
  • Sponsors AstraZeneca; MedImmune
  • Most Recent Events

    • 17 Jun 2017 Results of gene expression signature analysis of blood samlples from adult patients enrolled in two phase IIb studies including this study presented at the 18th Annual Congress of the European League Against Rheumatism
    • 23 Mar 2016 Results published in the Annals of the Rheumatic Diseases
    • 13 Dec 2015 Results of pharmacokinetic modelling published in the British Journal of Clinical Pharmacology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top